GlobeNewsWire
20 Jul 2026, 15:47 UTC · 13h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
An executive at Immix Biopharma, operating under the name 'Richard Graydon,' was allegedly a Rhode Island most-wanted fugitive named Ronald Fischer. — Severe governance failure and the employment of a fugitive executive create significant reputational risk and distrust in corporate oversight.
-0.80The law firm Block & Leviton is investigating Immix Biopharma for potential federal securities law violations. — The threat of a class-action lawsuit and regulatory scrutiny often leads to sustained downward pressure on stock prices.
-0.60Immix Biopharma shares fell approximately 10.83% on the day reports of the executive's identity circulated. — Confirms immediate negative market reaction and establishes a baseline for investor loss.
-0.40Continue reading
6 related stories
Search tags
Immix Biopharma terminated the executive on July 17, 2026, claiming there was no material effect on the business due to his short tenure. — The company's attempt to mitigate damage by claiming the impact was non-material provides a slight counter-narrative to the scandal.
+0.20Which stocks this story touches
The company is under investigation for securities fraud and shares fell over 10% following reports that an executive was a fugitive.
The company is being investigated by a law firm for potential securities law violations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
9h ago
